Results 41 to 50 of about 590,194 (288)

Meningococcal vaccine evolution

Clinical Management Issues, 2012
Neisseria meningitidis is a leading cause of bacterial sepsis and meningitis worldwide. Although polysaccharide and glycoconjugate vaccines have been developed for serogroups A, C, Y and W-135, currently there are no broadly effective vaccines available for the prevention of meningococcal B disease.
BONA, Gianni, Guidi C.
openaire   +6 more sources

The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae

bioRxiv, 2020
There is a pressing need for a gonorrhea vaccine due to the high disease burden associated with gonococcal infections globally and the rapid evolution of antibiotic resistance in Neisseria gonorrhoeae (Ng).
I. Leduc, Kristie L. Connolly, Afrina Begum, Knashka Underwood, N. Rahman, S. Darnell, J. T. Balthazar, W. Shafer, A. Macintyre, G. Sempowski, A. Jerse   +10 more
semanticscholar   +1 more source

Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease

Canada Communicable Disease Report, 2020
Background: Trumenba™, a bivalent, factor-H binding protein meningococcal serogroup B (MenB-fHBP) vaccine was authorized for use in Canada in October 2017 for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis ...
Robyn Harrison, Robert Stirling, Oliver Baclic, Wendy Vaudry   +3 more
doaj   +1 more source

A space-time conditional intensity model for invasive meningococcal disease occurrence [PDF]

Biometrics 68, 607--616, 2015
A novel point process model continuous in space-time is proposed for quantifying the transmission dynamics of the two most common meningococcal antigenic sequence types observed in Germany 2002-2008. Modelling is based on the conditional intensity function (CIF) which is described by a superposition of additive and multiplicative components.
arxiv   +1 more source

Meningococcal vaccine [PDF]

Human Vaccines & Immunotherapeutics, 2012
Meningococcal meningitis is caused by Neisseria meningitidis, a gram-negative, aerobic, encapsulated diplococcus. Meningococci are divided into numerous serogroups based on the composition of their capsular polysaccharide (Ps) antigens. At least 13 serogroups have been described: A, B, C, D, 29E, H, I, K, L, W-135, X, Y and Z.
Pardeep Khanna, Ramesh Verma
openaire   +3 more sources

Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal.

Journal of the American Medical Association (JAMA), 2020
Importance A 4-component meningococcus group B vaccine (4CMenB) is the only vaccine in use to prevent group B invasive meningococcal disease in young children, but no matched controlled studies have evaluated it.
F. Rodrigues, R. Marlow, M. J. Simões, L. Danon, S. Ladhani, A. Finn   +5 more
semanticscholar   +1 more source

Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool That Exploits Genomic Data in Public Health and Clinical Microbiology Applications

Journal of Clinical Microbiology, 2020
As microbial genomics makes increasingly important contributions to clinical and public health microbiology, the interpretation of whole-genome sequence data by nonspecialists becomes essential. In the absence of capsule-based vaccines, two protein-based
C. Rodrigues, C. Rodrigues, K. Jolley, Andrew Smith, Andrew Smith, J. Cameron, I. Feavers, M. Maiden   +7 more
semanticscholar   +1 more source

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series

Human Vaccines & Immunotherapeutics, 2023
To explore the impact on timely series completion of initiating the HPV vaccine series prior to other vaccines in the adolescent platform (Tdap or meningococcal vacccines), we created a cohort of children aged 9 in 2015 who were continuously enrolled ...
Sidika Kajtezovic, Jake R. Morgan, Stephen Fiascone, Heather M. Brandt, Rebecca B. Perkins   +4 more
doaj   +1 more source

Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016

MMWR. Morbidity and mortality weekly report, 2017
Two serogroup B meningococcal (MenB) vaccines are currently licensed for use in persons aged 10-25 years in the United States. The two vaccines are MenB-FHbp (Trumenba, Pfizer, Inc.) (1) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals, Inc.) (2).
M. Patton, D. Stephens, Kelly L. Moore, Jessica R Macneil   +3 more
semanticscholar   +1 more source

VaccineLies: A Natural Language Resource for Learning to Recognize Misinformation about the COVID-19 and HPV Vaccines [PDF]

arXiv, 2022
Billions of COVID-19 vaccines have been administered, but many remain hesitant. Misinformation about the COVID-19 vaccines and other vaccines, propagating on social media, is believed to drive hesitancy towards vaccination. The ability to automatically recognize misinformation targeting vaccines on Twitter depends on the availability of data resources.
arxiv